-
7m 12sPart 1 | Session 5 Efficacy and Safety of CagriSema in REDEFINE 1 and 2
-
4m 46sPart 1 | Session 1 PATHWEIGH: Weight Management in Primary Care
-
6m 23sPart 1 | Session 2 MariTide Treatment for Obesity in Patients with or without Type 2 Diabetes
-
9m 52sPart 1 | Session 3 Clinical Implications of the STRIDE Study for Endocrinologists
ADA 2025 - Final results from the CATALYST trial show mifepristone significantly improved glucose control in patients with hypercortisolism and difficult-to-control diabetes.
We are joined by Dr John Buse (University of North Carolina, Chapel Hill, US) to discuss phase 4 results from CATALYST (NCT05772169), a randomised, placebo-controlled, multi-center trial investigating the safety and efficacy of mifepristone treatment of hypercortisolism in patients with difficult-to-control T2D.
Findings showed that patients who recieved mifepristone treatment had a clinically meaningful and statistically significant reduction in hemoglobin A1c, and had significantly reduced body weight and waist circumference compared to patients who received placebo.
Interview Questions:
- What is the background behind the CATALYST trial?
- What was the study design and patient population?
- What were the key findings?
- What are the take-home messages for practice?
- What further research is needed in this area?
Recorded remotely from Chapel Hill, 2025.
Editors: Yazmin Sadik, Jordan Rance
Videographer: David Ben-Harosh
Support: This is an independent interview produced by Radcliffe CVRM.
Watch Expert Interviews sharing the late-breaking trial data from the American Diabetes Association's Scientific Sessions 2025.
More from this programme
Part 1
Expert Interviews
Faculty Biographies
John Buse
Chief of the Division of Endocrinology and Metabolism, Director of the Diabetes Care Center and Executive Associate Dean for Clinical Research at UNC
Dr Buse’s practice combines clinical care, research and education. He has received international recognition for innovative clinical care and efforts at prevention of type 1 diabetes, type 2 diabetes and their complications. He practices patient-centered care focusing on developing treatment programs in collaboration with patients that meet their needs and expectations. He works with teams of investigators in diabetes clinical trials, comparative effectiveness research and translation of basic science research towards clinical application. Current projects focus in novel treatments including development of glucose-responsive insulin, cardiovascular safety and efficacy of diabetes drugs and developing the evidence-base for treatment guidelines of the future in diabetes care.
Dr Buse also plays a significant role in research administration, having been Executive Associate Dean for Clinical Research since 2011 and Director of the NC Translational and Clinical Sciences…
Comments